Table 2.
KRAS Status Subgroup Analysis of the Clinical Features of Study Patients
|
KRAS Wild Type (N = 18) |
KRAS Mutated (N = 23) |
P | |
|---|---|---|---|
| Sex, N (%) | .987 | ||
| Male | 11 (61.1) | 14 (60.9) | |
| Female | 7 (38.9) | 9 (30.1) | |
| Median age (range), years | 63 (36-85) | 61 (37-82) | .651 |
| EGFR status, N (%) | .026 | ||
| Positive | 9 (50.0) | 19 (82.6) | |
| Negative | 9 (50.0) | 4 (17.4) | |
| Tumor sidedness | .363 | ||
| Left side | 17 (94.4) | 19 (82.6) | |
| Right side | 1 (5.6) | 4 (17.4) | |
| UGT1A1 status | .421 | ||
| *1/*1 | 16 (88.9) | 17 (73.9) | |
| *1/*28 | 2 (11.1) | 5 (21.7) | |
| *28/*28 | 0 (0) | 1 (4.3) | |
| Irinotecan dose, N (%), mg/m2 | .375 | ||
| 260 | 5 (27.8) | 2 (8.7) | |
| 240 | 3 (16.7) | 2 (8.7) | |
| 210 | 1 (5.6) | 2 (8.7) | |
| 180 | 9 (50.0) | 16 (69.6) | |
| 120 | 0 (0.0) | 1 (4.3) | |
| Best objective response, N (%) | .190 | ||
| PR | 3 (16.7) | 1 (4.3) | |
| SD | 10 (55.6) | 10 (43.5) | |
| PD | 5 (27.8) | 12 (52.2) | |
| DCR, N (%) | 13 (72.2) | 11 (47.8) | .116 |
| AEs | .019 | ||
| Grade ≧3 | 15 (83.3) | 11 (47.8) | |
| Grade <3 | 3 (16.7) | 12 (52.2) |
EGFR, epidermal growth factor receptor; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; AEs, adverse events.